Stop wasting resources on antibodies

that don’t deliver

When performance matters—such as detecting or quantifying trace amounts of analytes—antibody affinity can make or break your results. Antibodies with ultra-high affinities (10⁻⁹ to 10⁻¹² M) offer better signal-to-noise ratios, allowing you to detect even the smallest quantities of target with confidence and reliability.

Ultra high affinity (10-9 to 10-12 M) for the most demanding applications

Whether you’re detecting or quantifying trace amounts of analytes, affinity is one of the key properties of a successful antibody. At ProteoGenix, we routinely generate antibodies with nanomolar to picomolar affinities. This level of binding strength improves your signal-to-noise ratio, making it easier to detect even the smallest amounts of target — so you can trust your results with full confidence.

A streamlined, risk-free development process

  1. Share your project – Simply provide your target, intended application, and specific technical requirements.
  2. Receive a tailored strategy – Based on your goals, the most effective antibody development approach is selected from among multiple advanced platforms.
  3. Test before committing – Antibodies are pre-screened in-house, and only the best candidates are sent to your lab for testing.
  4. No win, no fee – You only pay if the antibody meets your performance criteria.

This performance-based model is backed by experience from 2000+ successful antibody development projects.

Book a Call

Guaranteed applications – Validated across 11 applications

The No Win – No Fee guarantee applies to a wide range of techniques, including:

ELISA (Standard, Sandwich, Competitive)
Western Blot
Flow cytometry (FACS)
Immuno fluorescence
Immuno precipitation
Immuno histochemistry / Immuno histofluorescence
Lateral flow assay (LFA)
Modification specific detection

Monoclonal & polyclonal antibody expertise – Solutions for every antibody challenge

 

5 advanced antibody discovery platforms to fit to all your needs

Not all projects are the same. That’s why multiple antibody discovery platforms are available to align with your scientific objectives.

 

Expert guidance and strategy design with dedicated scientific experts

Your project is guided by experts with deep scientific backgrounds—PhD-level account managers and seasoned scientists—who help define strategy, interpret results, and keep your development on track.

Proven success in complex scenarios

From ultra-sensitive detection to multiplex assay development, customized antibodies are designed to overcome even the most complex R&D challenges. Examples of successfully delivered projects include:

  • Detection of low-abundance analytes (nM to pM range)
  • Accurate quantification of low-concentration targets
  • Antibodies optimized for challenging sample matrices
  • Simultaneous detection of multiple analytes (multiplexing)
  • Specific detection of mutated proteins with no cross-reactivity

And this is only a glimpse—any complex requirement can be addressed through tailored strategies and cutting-edge technology. Having a project in mind? Let’s talk!

 

Full ownership and transparency

All antibody development services are 100% royalty-free, with no licensing restrictions or hidden fees. You retain full ownership of the results and can move forward with complete freedom.

Beyond standard services – A commitment to your success

At ProteoGenix, we don’t just develop antibodies—we ensure your success. Every project benefits from:

  • Integrated technology watch: We offer access to our dedicated technology watch platform, optimizing protocols especially for your project’s success.
  • Backup strategies for complex projects: With multiple development platforms at our disposal, we can anticipate alternative approaches and activate them upon request.

Minimize risk, accelerate timelines, and secure the antibody you need—with performance guaranteed!

Book a Call

What our clients say

We collaborated on a project on generating a monoclonal antibody that recognizes a one-amino-acid mutation in a cancer-associated cell-surface protein. Although the project was technically challenging, we succeeded in generating a hybridoma clone that produced the desired antibody. In the course of the project, we found additional clones that recognized adjacent epitopes and Proteogenix put forth an effort to perform additional subclonings in order to ensure the delivery of clones that perfectly work. In summary, Proteogenix always strived to ensure maximal quality of the product and customer satisfaction, and the account Manager provided prompt and competent support at any time.

I contacted ProteoGenix regarding the generation of monoclonal antibodies for the detection of a chemokine. ProteoGenix generated for us multiple monoclonal antibodies to detect the chemokine by ELISA, western blot and to test these antibodies in functional assays. They provided an excellent service, with regular updates, quick response to our queries and an excellent delivery of the product. I recommend their service for their efficacy and professionalism.

We contacted ProteoGenix to develop repertoires of specific antibodies against three antigens sharing high homology. As determined by ELISA, ProteoGenix developed several specific antibodies that exhibited no cross-reactivity with the other antigens. We appreciated their proactive approach to increase our chances of success (e.g., performing fusions at their own risks). We are satisfied with the services of the company.

We are thrilled with the success we’ve achieved through our collaboration with ProteoGenix in developing monoclonal antibodies targeting our protein. The antibodies they produced were not only highly selective but also demonstrated exceptional affinity for our target, significantly advancing our research.
ProteoGenix impressed us with their efficiency and speed throughout the process. Their commitment to providing excellent customer service made our experience even better, as they were always available to address our questions and concerns.
We highly recommend ProteoGenix to anyone in need of high-quality antibody development.

We requested ProteoGenix’s services for the generation of anti-protein monoclonal antibodies to be used in our research. One antibody turned out to be an extremely good reagent, which received strong interest from Merck-Millipore and was eventually sold as part of a CNRS licence agreement in order to be added to Merck-Millipore’s products catalog. I’m definitely satisfied with ProteoGenix’s services!

Trusted by leading institutions

  • Cizzle Biotechnology

    Early lung cancer detection antibodies.

  • University of Ulm

    Breast cancer diagnostic antibodies.

  • CNRS & Merck-Millipore

    Commercialized antibodies for advanced research.

Featured publications

PC Maity et al., IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. PNAS 117, (8) 4320-27 (2020). https://doi.org/10.1073/pnas.1913810117

N Yacov et al., MOSPD2 is a therapeutic target for the treatment of CNS inflammation. Clin Exp Imm 201, (2) 105-20 (2020). https://doi.org/10.1111/cei.13448

A Surribas et al., Monoclonal antibody-based immunosensor for the electrochemical detection of chlortoluron herbicide in groundwaters. Biosensors 11, (12) 513 (2021). https://doi.org/10.3390/bios11120513

FAQs: Diagnostic & Research Antibodies

Ready to develop your next high-performance diagnostic or research antibody? Contact us today!

You can also easily order our services on:

Scientist.com

ScienceExchange.com